Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982186 · ClinicalTrials.gov registry record · Phase 2
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
A Phase 2 study, sponsored by Janssen Sciences Ireland UC.
- Completed
- Registry status
- Phase 2
- Development phase
- 471
- Enrollment target
NCT03982186 is a Phase 2 study that has completed, run by Janssen Sciences Ireland UC. The registered enrollment target is 471 participants.
The verdict
NCT03982186, a Phase 2 study, has completed, sponsored by Janssen Sciences Ireland UC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 471 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA (with and without JNJ-56136379) and of JNJ-56136379+NA.
Interventions
- DRUG JNJ-56136379
- DRUG JNJ-73763989
- DRUG Placebo for JNJ-73763989
- DRUG Placebo for JNJ-56136379
- DRUG Nucleos(t)ide Analog (NA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03982186
The ClinicalTrials.gov registry entry for NCT03982186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Sciences Ireland UC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which JNJ-56136379 is the first listed.
NCT03982186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03982186 about?
NCT03982186 is a clinical study titled "A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection". The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA (with and without JNJ-56136379) and of JNJ-56136379+NA.
What is the current status of trial NCT03982186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 471 participants. The study started on 2019-08-01. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT03982186?
The interventions under investigation include: JNJ-56136379 (DRUG), JNJ-73763989 (DRUG), Placebo for JNJ-73763989 (DRUG), Placebo for JNJ-56136379 (DRUG), Nucleos(t)ide Analog (NA) (DRUG).
Who is sponsoring clinical trial NCT03982186?
This trial is sponsored by Janssen Sciences Ireland UC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.